These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Role of enoxaparin in the invasive management of the ACS patient. Hermiller JB J Invasive Cardiol; 2004 Feb; 16(2):52-3. PubMed ID: 14760189 [No Abstract] [Full Text] [Related]
5. Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes. Shimpi RA J Invasive Cardiol; 2003 Aug; 15(8):460-5. PubMed ID: 12890880 [No Abstract] [Full Text] [Related]
9. Updated guidelines for percutaneous coronary intervention: what are the most important changes? Spencer BK; Smith SC Pol Arch Med Wewn; 2008 Mar; 118(3):96-7. PubMed ID: 18476453 [No Abstract] [Full Text] [Related]
11. [Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients]. Münzel TF; Post F Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S215-8. PubMed ID: 17109252 [TBL] [Abstract][Full Text] [Related]
12. Acute coronary syndromes: should women receive less antithrombotic medication than men? Danchin N Heart; 2004 Apr; 90(4):363-6. PubMed ID: 15020498 [TBL] [Abstract][Full Text] [Related]
13. [Eptifibatide in acute coronary syndromes. Comments on the practice guidelines in antithrombotic treatment]. Díaz de Rojas F; Ponte A; Cuenllas E Rev Esp Cardiol; 2000 Feb; 53(2):302-3. PubMed ID: 10734766 [No Abstract] [Full Text] [Related]
14. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ; JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903 [TBL] [Abstract][Full Text] [Related]
15. Antithrombotic therapy in acute coronary syndromes. Sabatine MS; Jang IK Acta Cardiol; 1999 Feb; 54(1):3-29. PubMed ID: 10214473 [No Abstract] [Full Text] [Related]
16. Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy. Kwa AT; Rogers JH J Interv Cardiol; 2008 Apr; 21(2):107-17. PubMed ID: 18248357 [TBL] [Abstract][Full Text] [Related]
17. [Use of platelet glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndrome and coronary intervention]. Kakuta T; Kishi Y; Numano F Nihon Rinsho; 1998 Oct; 56(10):2630-4. PubMed ID: 9796330 [TBL] [Abstract][Full Text] [Related]
18. [Antithrombotic treatment in acute coronary syndrome]. Darius H; Rupprecht HJ; Genth-Zotz S; Wittlinger T; Zotz R Dtsch Med Wochenschr; 2014 Jan; 139 Suppl 1():S17-22. PubMed ID: 24446037 [No Abstract] [Full Text] [Related]
19. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ; J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319 [TBL] [Abstract][Full Text] [Related]